EQL Pharma () | Spotlight

EQL Pharma is a pharmaceutical company. Currently, the focus is on development of niche and specialised pharmaceuticals, including everything from pharma for the treatment of diabetes, enlargement of blood vessels, as well as various infections and allergies. Primarily business is found in the Nordic market. EQL Pharma was founded in 2006 and is based in Lund.

Quotes for EQL Pharma AB

Right Now

+/-
%
Latest
High
Low
Volume
Turnover ()
Time (Latest trade)

Board

CEO

Axel Schörling

Chairperson of the Board

Christer Fåhraeus

Board

Anders Månsson
Linda Neckmar
Per Ollermark
Per Svangren
Rajiv I. Modi

Articles of association

News

2024-06-28 10:15:00 EQL Pharma AB offentliggör prospekt för listbyte till Nasdaq Stockholm
2024-06-28 10:15:00 EQL Pharma AB publishes prospectus for list change to Nasdaq Stockholm
2024-06-28 07:00:00 EQL Pharma Årsredovisning 2023/2024
2024-06-12 16:20:00 EQL Pharma AB has been approved for listing on Nasdaq Stockholm
2024-06-12 16:20:00 EQL Pharma AB har godkänts för notering på Nasdaq Stockholm

Analysis

2024-05-17 Kalqyl: EQL Pharma: Rapportkommentar Q4’23/24 - Kalqyl
2024-04-03 Affärsvärlden: EQL Pharma: Tillväxt på recept - AFV
2024-02-19 Kalqyl: EQL Pharma: Rapportkommentar Q3’23/24 - Kalqyl
2023-11-23 : EQL Pharma: A repeat prescription for growth - Carnegie
2023-11-22 Kalqyl: EQL Pharma: Rapportkommentar Q2’23/24 - Kalqyl

Videos

Largest Owners

Name	Capital %	Votes %	Date
Cadila Pharmaceuticals Ltd	30,00	30,00	2024-06-26
Christer Fåhraeus	24,21	24,21	2024-06-26
SEB Fonder	4,33	4,33	2024-06-26
Consensus Asset Management	2,86	2,86	2024-06-30
Avanza Pension	2,73	2,73	2024-06-26
Nordnet Pensionsförsäkring	2,34	2,34	2024-06-26
Sten Irwe	1,83	1,83	2024-06-26
Carnegie Fonder	1,51	1,51	2024-06-30
Axel Schörling	1,07	1,07	2024-05-24
Göran Nordlund (Fore C Investments)	1,06	1,06	2024-06-30

EQL Pharma AB